Axsome Therapeutics Inc

Axsome Therapeutics, Inc. embarked on its journey in January 2012, founded in New York, New York, by Herriot Tabuteau, MD, who continues to lead the company as its Chairman and CEO. From its inception, Axsome has been driven by a clear vision: to develop innovative therapies for challenging central nervous system (CNS) disorders where treatment options are limited or inadequate. Recognizing the significant unmet medical needs in this space, a field many larger pharmaceutical companies had shied away from due to inherent complexities, Dr. Tabuteau and his team committed to leveraging novel mechanisms of action and cutting-edge research to make a meaningful difference in the lives of patients.

The company's early years were focused on building a robust pipeline and navigating the rigorous path of clinical development. A pivotal moment arrived in November 2015 when Axsome Therapeutics successfully completed its Initial Public Offering (IPO) on the NASDAQ exchange, raising approximately $57.5 million in gross proceeds. This infusion of capital was crucial, enabling the company to advance its promising CNS pipeline candidates through various clinical trial phases. Over the subsequent years, Axsome achieved several key milestones, including positive Phase 3 results for its novel drug candidates and strategic acquisitions, such as Sunosi® (solriamfetol) in 2021, which diversified its portfolio with an approved, revenue-generating product. This strategic move, coupled with the eventual FDA approval of its internally developed therapies like Auvelity® for Major Depressive Disorder, marked Axsome's significant transition from a clinical-stage entity to a commercial-stage biopharmaceutical company. Today, Axsome continues to expand its market presence, driven by the sales of its approved products and the progression of its late-stage development programs, all while remaining steadfast in its mission to address critical gaps in care for individuals living with serious CNS conditions.